An integrative approach for the transplantation of high-risk sensitized patients

Transplantation

Volumn 90, Issue 6, 2010, Pages 645-653

  Morath, Christian ^a   Beimler, Jörg ^a   Opelz, Gerhard ^a   Ovens, Jörg ^a   Scherer, Sabine ^a   Schmidt, Jan ^a   Schmied, Bruno ^a   Gross, Marie Luise ^a   Schwenger, Vedat ^a   Zeier, Martin ^a   Süsal, Caner ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Antibody mediated rejection; Apheresis; Kidney transplantation; Presensitization; Rituximab

Indexed keywords

BASILIXIMAB; CD20 ANTIBODY; CREATININE; HLA ANTIGEN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; RITUXIMAB; TACROLIMUS; ANTIBODY; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; ADULT; AGED; ALGORITHM; APHERESIS; ARTICLE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DELAYED GRAFT FUNCTION; DRUG DOSE REDUCTION; FEMALE; GRAFT RECIPIENT; GRAFT SURVIVAL; HIGH RISK PATIENT; HISTOCOMPATIBILITY; HUMAN; INFECTIOUS COMPLICATION; KIDNEY TRANSPLANTATION; LIVING DONOR; MALE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; SINGLE DRUG DOSE; ALLOTRANSPLANTATION; CADAVER; DONOR; DRUG COMBINATION; FOLLOW UP; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; INFORMED CONSENT; LENGTH OF STAY; MIDDLE AGED; PROCEDURES; RISK FACTOR; YOUNG ADULT;

ADULT; AGED; ANTIBODIES; CADAVER; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; GRAFT SURVIVAL; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFORMED CONSENT; KIDNEY TRANSPLANTATION; LENGTH OF STAY; MIDDLE AGED; RISK FACTORS; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 77957277137     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181ea3985     Document Type: Article

References (40)

1. Jordan SC, Pescovitz MD. Presensitization: The problem and its management. Clin J Am Soc Nephrol 2006; 1: 421.
2. Susal C, OpelzG. Kidney graft failure and presensitization against HLA class I and class II antigens. Transplantation 2002; 73: 1269.
3. Doxiadis, II, Smits JM, Persijn GG, et al. It takes six to boogie: Allocating cadaver kidneys in Eurotransplant. Transplantation 2004; 77: 615.
4. Opelz G. Non-HLA transplantation immunity revealed by lymphocy-totoxic antibodies. Lancet 2005; 365: 1570.
5. Zachary AA, Montgomery RA, Ratner LE, et al. Specific and durable elimination of antibody to donor HLA antigens in renal-transplant patients. Transplantation 2003; 76: 1519.
6. Montgomery RA, Zachary AA, Racusen LC, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation2000; 70: 887.
7. Jordan SC, Tyan D, Stablein D, et al. Evaluation of intravenous immuno-globulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: Report of the NIH IG02 trial. J Am Soc Nephrol 2004; 15: 3256.
8. Stegall MD, Gloor J, Winters JL, et al. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levelsof donor specific alloantibody.Am JTransplant2006; 6:346.
9. Glotz D, Antoine C, Julia P, et al. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant 2002; 2: 758.
10. Beimler JH, Morath C, Schmidt J, et al. Successful deceased-donor kidney transplantation in crossmatch-positive patients with peritrans-plant plasma exchange and Rituximab. Transplantation 2009; 87: 668.
11. Stegall MD, Dean PG, GloorJ.Mechanisms ofalloantibody production in sensitized renal allograft recipients. Am J Transplant 2009; 9: 998.
12. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969; 280: 735.
13. Claas FH, Witvliet MD, Duquesnoy RJ, et al. The acceptable mismatch program as a fast tool for highly sensitized patients awaiting a cadaveric kidney transplantation: Short waiting time and excellent graft outcome. Transplantation 2004; 78: 190.
14. Susal C, Dohler B, Opelz G. Presensitized kidney graft recipients with HLA class I and II antibodies are at increased risk for graft failure: A Collaborative Transplant Study report. Hum Immunol 2009; 70: 569.
15. Book BK, Agarwal A, Milgrom AB, et al. New crossmatch technique eliminates interference by humanized and chimeric monoclonal antibodies. Transplant Proc 2005; 37: 640.
16. Susal C, Dohler B, Sadeghi M, et al. HLA antibodies and the occurrence of early adverse events in the modern era of transplantation: A collaborative transplant study report. Transplantation 2009; 87: 1367.
17. Haririan A, Nogueira J, Kukuruga D, et al. Positive cross-match living donor kidney transplantation: Longer-term outcomes. Am J Transplant 2009; 9: 536.
18. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357: 2601.
19. Humar A, Michaels M. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006; 6: 262.
20. Zeier M, Kasiske B. Initiatives focusing on transplantation highlight talks at NKF annual meeting. Nephrol News Issues 2009; 23: 51.
21. De Meester J, Doxiadis II, Persijn GG, et al. Renal transplantation of highly sensitised patients via prioritised renal allocation programs. Shorter waiting time and above-average graft survival. Nephron 2002; 92: 111.
22. Van Den Berg-Loonen EM, Billen EV, Voorter CE, et al. Clinical relevance of pretransplant donor-directed antibodies detected by single antigen beads in highly sensitized renal transplant patients. Transplantation 2008; 85: 1086.
23. Gupta A, Iveson V, Varagunam M, et al. Pretransplant donor-specific antibodies in cytotoxic negative crossmatch kidney transplants: Are they relevant? Transplantation 2008; 85: 1200.
24. Mai ML, Ahsan N,Wadei HM, et al. Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin. Transplantation 2009; 87: 227.
25. Lorenz M, Regele H, Schillinger M, et al. Peritransplant immunoad-sorption: A strategy enabling transplantation inhighly sensitized cross-match-positive cadaveric kidney allograft recipients. Transplantation 2005; 79: 696.
26. Tyden G, Kumlien G, Genberg H, et al. ABO incompatible kidney transplantations without splenectomy, using antigen-specific immu-noadsorption and rituximab. Am J Transplant 2005; 5: 145.
27. Sonnenday CJ, Warren DS, Cooper M, et al. Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am J Transplant 2004; 4: 1315.
28. Pescovitz MD. B cells: A rational target in alloantibody-mediated solid organ transplantation rejection. Clin Transplant 2006; 20: 48.
29. Dittrich E, Schmaldienst S, Derfler K. [Plasma exchange and immuno-adsorption]. Wien Klin Wochenschr 2007; 119(5-6 suppl 1): 39.
30. Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008; 359: 242.
31. Qiu J, Cai J, Terasaki PI, et al. Detection of antibodies to HLA-DP in renal transplant recipients using single antigen beads. Transplantation 2005; 80: 1511.
32. KinukawaT,Kato M,Terasaki PI, et al. Retrospective antibody analysis of thirty patients with kidney graft failure. Clin Transpl 2006: 291.
33. Karpinski M, Rush D, Jeffery J, et al. Flow cytometric crossmatching in primary renal transplant recipients with a negative anti-human globulin enhanced cytotoxicity crossmatch. J Am Soc Nephrol 2001; 12: 2807.
34. Vieira CA, Agarwal A, Book BK, et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. Transplantation 2004; 77: 542.
35. YanabaK, Bouaziz JD, Matsushita T, et al. B-lymphocyte contributions to human autoimmune disease. Immunol Rev 2008; 223: 284.
36. Salama AD, Pusey CD. Drug insight: Rituximab in renal disease and transplantation. Nat Clin Pract Nephrol 2006; 2: 221.
37. Seron D, Moreso F, Bover J, et al. Early protocol renal allograft biopsies and graft outcome. Kidney Int 1997; 51: 310.
38. Rush DN, Jeffery JR, Gough J. Sequential protocol biopsies in renal transplant patients: Repeated inflammationisassociated with impaired graft function at 1 year. Transplant Proc 1995; 27: 1017.
39. Shapiro R, Randhawa P, Jordan ML, et al. An analysis of early renal transplant protocol biopsies\The high incidence of subclinical tubu-litis. Am J Transplant 2001; 1: 47.
40. Grimbert P, Mansour H, Desvaux D, et al. The regulatory/cytotoxic graft-infiltrating T cells differentiate renal allograft borderline change from acute rejection. Transplantation 2007; 83: 341.